Gain(1)(q21) is an unfavorable genetic prognostic factor for patients with relapsed multiple myeloma treated with thalidomide but not for those treated with bortezomib.
Smetana J, Berankova K, Zaoralova R, Nemec P, Greslikova H, Kupska R, Mikulasova A, Frohlich J, Sevcikova S, Zahradova L, Krejci M, Sandecka V, Almasi M, Kaisarova P, Melicharova H, Adam Z, Penka M, Jarkovsky J, Jurczyszyn A, Hajek R, Kuglik P.
Smetana J, et al. Among authors: zahradova l.
Clin Lymphoma Myeloma Leuk. 2013 Apr;13(2):123-30. doi: 10.1016/j.clml.2012.11.012. Epub 2013 Jan 4.
Clin Lymphoma Myeloma Leuk. 2013.
PMID: 23291040